The dangers of mass drug administration of albendazole in Nepal, a Neurocysticercosis-endemic region.

IF 2.4 Q3 INFECTIOUS DISEASES
Tropical Diseases, Travel Medicine and Vaccines Pub Date : 2020-10-23 eCollection Date: 2020-01-01 DOI:10.1186/s40794-020-00122-2
Gaurav Nepal, Ghanshyam Kharel, Yow Ka Shing, Rajeev Ojha, Sujan Jamarkattel, Jayant Kumar Yadav, Himani Vyas, Dhiraj Poudyal, Ranjit Sah
{"title":"The dangers of mass drug administration of albendazole in Nepal, a Neurocysticercosis-endemic region.","authors":"Gaurav Nepal,&nbsp;Ghanshyam Kharel,&nbsp;Yow Ka Shing,&nbsp;Rajeev Ojha,&nbsp;Sujan Jamarkattel,&nbsp;Jayant Kumar Yadav,&nbsp;Himani Vyas,&nbsp;Dhiraj Poudyal,&nbsp;Ranjit Sah","doi":"10.1186/s40794-020-00122-2","DOIUrl":null,"url":null,"abstract":"<p><p>The majority of cases of Neurocysticercosis (NCC) are asymptomatic. Injudicious use of antihelmintics like albendazole (ALB) can cause cyst degeneration and perilesional inflammation, thus rendering asymptomatic individuals symptomatic with seizures, headache, vascular events, or cerebral edema. Mass drug administration (MDA) using ALB is a very common practice in developing countries like Nepal to contain transmission of soil-transmitted helminths (STH) and lymphatic filariasis (LF). Although the benefits of ALB-based MDA in the general population cannot be undermined, there can be severe consequences in certain groups, especially those with latent NCC. In this commentary, we discuss the effect it may have on such patients, and suggest potential solutions.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"6 ","pages":"22"},"PeriodicalIF":2.4000,"publicationDate":"2020-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s40794-020-00122-2","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tropical Diseases, Travel Medicine and Vaccines","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40794-020-00122-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

The majority of cases of Neurocysticercosis (NCC) are asymptomatic. Injudicious use of antihelmintics like albendazole (ALB) can cause cyst degeneration and perilesional inflammation, thus rendering asymptomatic individuals symptomatic with seizures, headache, vascular events, or cerebral edema. Mass drug administration (MDA) using ALB is a very common practice in developing countries like Nepal to contain transmission of soil-transmitted helminths (STH) and lymphatic filariasis (LF). Although the benefits of ALB-based MDA in the general population cannot be undermined, there can be severe consequences in certain groups, especially those with latent NCC. In this commentary, we discuss the effect it may have on such patients, and suggest potential solutions.

尼泊尔是神经囊虫流行地区,大规模给药阿苯达唑的危险。
神经囊虫病(NCC)的大多数病例是无症状的。不明智地使用阿苯达唑(ALB)等抗寄生虫药可引起囊肿变性和病灶周围炎症,从而使无症状个体出现癫痫发作、头痛、血管事件或脑水肿等症状。在尼泊尔等发展中国家,使用白蛋白b进行大规模给药(MDA)是一种非常普遍的做法,以遏制土壤传播的蠕虫(STH)和淋巴丝虫病(LF)的传播。尽管以白蛋白为基础的丙二醛在一般人群中的益处不能被削弱,但在某些人群中,特别是那些有潜伏性NCC的人群中,可能会有严重的后果。在这篇评论中,我们讨论了它可能对这些患者产生的影响,并提出了潜在的解决方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.20
自引率
0.00%
发文量
25
审稿时长
17 weeks
期刊介绍: Tropical Diseases, Travel Medicine and Vaccines is an open access journal that considers basic, translational and applied research, as well as reviews and commentary, related to the prevention and management of healthcare and diseases in international travelers. Given the changes in demographic trends of travelers globally, as well as the epidemiological transitions which many countries are experiencing, the journal considers non-infectious problems including chronic disease among target populations of interest as well as infectious diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信